Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, discusses the approval of luspatercept for the treatment of beta-thalassemia, as well as the ongoing Phase III trials of mitapivat- a pyruvate kinase activator- in both transfusion-dependent and independent patients. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
